Independent Review, Published in International Journal of Molecular Sciences, Supports Accuracy and Performance of Nucleix’s Bladder EpiCheck® Urine Test in Detecting Non-Muscle Invasive Bladder Cancer Recurrence
SAN DIEGO & REHOVOT, Israel–(BUSINESS WIRE)–Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced a published independent review of Bladder EpiCheck studies which showed high diagnostic accuracy and high performance for surveillance of disease recurrence in patients with non-muscle invasive bladder cancer (NMIBC).
Subscription Confirmation Required
Go to your email inbox
Go to the inbox of the email
address you just used to sign up.
Open the confirmation email
Find the email sent by us. It has the subject line
“Nucleix: Please Confirm Subscription” and I
sent from “info@nucleix.com”.
Click the confirmation link
Click on the link inside the <br>email and you’re good to go.